Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Patients with ≥1 prior line of therapy were ...

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed. We conducted a phase 1 clinical trial to ...

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024. In this segment, Dr. Morrison introduces the concept of ...

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...

Please provide your email address to receive an email when new articles are posted on . Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs.

The CheckMate 67T trials revealed that subcutaneous nivolumab was noninferior to intravenous nivolumab for the treatment of advanced or metastatic clear cell renal cell carcinoma. Subcutaneous ...

INCHEON, South Korea--(BUSINESS WIRE)--A new post-hoc analysis of a pivotal phase III randomised controlled clinical trial shows that the subcutaneous (SC) formulation of infliximab, Remsima ® (CT-P13 ...

According to the results of a single-center, prospective, crossover study, darbepoetin alfa—a hyperglycosylated, and therefore longer-acting, derivative of epoetin—is a more effective treatment for ...

Implementing subcutaneous opioid options in the emergency department significantly reduced reliance on intravenous administration.